



# Two Cell Assay

Resistance Test Vector      A-MLV env






Fig. 2

**Drug Resistance: NRTI, NNRTI, PI***Fig. 3*

# Drug Susceptibility Test Profile: Patient 487




Fig. 4A

# Drug Susceptibility Test Profile: Patient 487




Fig. 4B

# Drug Susceptibility Test Profile: Patient 487





Fig. 4C

## Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 5

# Drug Suseptability Test Profile: Patient 268




Fig. 6A



# Drug Suseptability Test Profile: Patient 268




Fig. 6B

# Drug Suseptability Test Profile: Patient 268





Fig. 6C

## Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 7A

## Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 7B

# Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 7C

# Drug Susceptibility Test Profile: Patient 302




Fig. 8A

# Drug Susceptibility Test Profile: Patient 302






Fig. 8B


# Drug Susceptibility Test Profile: Patient 302



RTV-Control IC50 = 0.19035  
RTV-302 IC50 = 0.06306



SQV-Control IC50 = 0.00524  
SQV-302 IC50 = 0.00238



ddl -Control IC50 = 23.14837  
ddl -302 IC50 = 22.13531

Fig. 8C



# Drug Susceptibility Test Profile: Patient 780




Fig. 8D

# Drug Susceptibility Test Profile: Patient 780







Fig. 8E

# Drug Susceptibility Test Profile: Patient 780






Fig. 8F

# Drug Susceptibility Test Profile: Patient 302 Virus Clones







Fig. 8G

## Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 8H

## Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 8I

## Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 8J

# Drug Susceptibility Test Profile: Patient 644







Fig. 9A



# Drug Susceptibility Test Profile: Patient 644




Fig. 9B

# Drug Susceptibility Test Profile: Patient 644






Fig. 9C




Fig. 9D